DA Davidson maintains Phreesia at Buy, raises price target to $15 from $13

DA Davidson reaffirmed its Buy rating for Phreesia and increased its price target to $15 from $13, citing a 22.3% upside from the Nov 18 close of $12.26.

Original reporting
Published Nov 19, 2026, 4:48 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 19, 2026, 4:55 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
DA Davidson maintains Phreesia at Buy, raises price target to $15 from $13 — source image
Decision brief

The 30-second read

Med
01

Why it matters

The price‑target increase signals a shift in analyst sentiment, which may attract short‑term buying.

02

Market read

Analyst upgrade could trigger modest price movement in Phreesia.

03

What to watch

Potential dilution from future financing rounds not addressed.

Relevance 6/10Novelty 6/10Timing: today

Background

Phreesia is a cloud‑based patient intake platform; analyst coverage is limited.

Market effects

May lift sentiment in the health‑tech sector.

Limited to US small‑cap market.

Minimal.

Counterpoint

Target raise could be premature if upcoming earnings miss expectations.

Key entities

  • DA Davidson

    Raised Phreesia price target to $15.

Related articles

$PHRMed

Phreesia’s (PHR) Profit Turnaround Meets A Cash-Strapped Client Base

Phreesia (PHR) reported Q2 2027 revenue of $129.5M and adjusted EBITDA of $32.9M, marking five straight quarters of positive net income. Revenue grew 10% YoY, with client count and revenue per client also increasing. The company reduced debt by $23M and credited AI for operational efficiencies. However, management warned of increased unpredictability in network solutions revenue due to financial strain on healthcare providers. Phreesia reaffirmed its full-year revenue and EBITDA guidance.

$PHRHighAI 8/10

Phreesia (PHR) Q2 2027 Earnings Call Transcript

Phreesia (PHR) reported Q2 2027 revenue of $129.5M, up 10% YoY, with adjusted EBITDA of $32.9M and net income of $1.9M. AHSCs grew 6% to 4,744. Full-year guidance: revenue $510M-$520M, adjusted EBITDA $125M-$135M. Management noted variability in revenue forecasting and economic pressures on healthcare providers.

$PHRMed

Why Phreesia Stock Got Knocked Down Today

Phreesia (PHR) stock fell 7% Tuesday due to bearish sentiment after Q2 earnings and a downgrade by Raymond James analyst John Ransom. Ransom cited declining organic revenue growth and AI spending pressures. Despite a 10% revenue increase, concerns remain about future performance and market constraints.

$PHRMed

Why Phreesia Stock Tumbled Today

Phreesia (PHR) shares fell 6.33% after reporting Q2 2027 revenue of $129.5M, up 10% YoY, and GAAP net income of $1.9M. While revenue beat estimates, earnings per share missed expectations. The company maintained full-year guidance and highlighted recent product launches.